Changes in the Transmission Dynamics of the HIV Epidemic after the Wide-Scale Use of Antiretroviral Therapy Could Explain Increases in Sexually Transmitted Infections: Results from Mathematical Models

Sexually Transmitted Diseases

Volumn 31, Issue 2, 2004, Pages 100-112

  Boily, Marie Claude ^a   Bastos, Francisco I ^b   Desai, Kamal ^a   Mâsse, Benoît ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; EPIDEMIC; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MATHEMATICAL MODEL; SEXUALLY TRANSMITTED DISEASE; TREATMENT FAILURE; VIRUS INFECTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE OUTBREAKS; DISEASE TRANSMISSION, HORIZONTAL; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MODELS, STATISTICAL; PREVALENCE; RISK-TAKING; SEXUALLY TRANSMITTED DISEASES; WASHINGTON;

EID: 0942268861     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.OLQ.0000112721.21285.A2     Document Type: Article

References (106)

1. Centers for Disease Control and Prevention. Increase in unsafe sex and rectal gonorrhea among men who have sex with men-San Francisco, California, 1994-1997. MMWR Morb Mortal Wkly Rep 1999; 48:45-48.
2. Fox KK, del Rio C, Holmes KK, et al. Gonorrhea in the HIV era: a reversal in trends among men who have sex with men. Am J Public Health 2001; 91:959-964.
3. Van de Ven P, Prestage G, French J, et al. Increase in unprotected anal intercourse with casual partners among Sydney gay men in 1996-1998. Aust N Z Public Health 1998; 22:814-818.
4. Dodds JP, Nardone A, Mercey DE, Johnson AM. Increase in high-risk sexual behaviour among homosexual men, London 1996-8: cross sectional, questionnaire study. BMJ 2001; 320: 1510-1511.
5. Stall RD, Hays RB, Waldo CR, Ekstrand M, McFerland W. The gay '90s: a review of research in the 1990s on sexual behavior and HIV risk among men who have sex with men. AIDS 2000; 14(suppl 3):S1-S14.
6. Stolte IG, Dukers NH, de Wit JB, Fennema JS, Coutinho RA. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect 2001; 77:184-186.
7. Laporte A. A new decline in preventive behaviours among homosexual men: the role of highly active antiretroviral therapy? Euro Surveill 2002; 7:15-16.
8. Stolte G, Dukers NH, de Wit JB, Fennema H, Coutinho RA. A summary report from Amsterdam: increase in sexually transmitted diseases and risky sexual behaviour among homosexual men in relation to the introduction of new anti-HIV drugs. Euro Surveill 2002; 7:19-22.
9. Dubois-Arber F, Moreau-Gruet F, Jeannin A. Men having sex with men and HIV/AIDS prevention in Switzerland: 1987-2000. Euro Surveill 2002; 7:16-18.
10. Perez K, Casabona J. Monitoring HIV prevalence and behaviour of men who have sex with men in Barcelona, Spain. Euro Surveill 2002; 7:23-28.
11. International Collaboration on HIV Optimism. HIV treatments Optimism among gay men: an international perspective. J Acquir Immune Defic Syndr 2003; 33:545-550.
12. Dilley JW, Woods WJ, MacFarland W. Are advances in treatment changing views about high-risk sex? N Engl J Med 1997; 337:501-502.
13. Elford J, Bolding G, Sherr L. HIV optimism: fact or fiction? Focus 2001; 16:1-4.
14. Marseille E, Hofmann PB, Kahn JG. HIV prevention before ART in sub-Saharan Africa. Lancet 2002; 359:1851-1856.
15. Hosseinipour M, Cohen MS, Vernazza PL, Kashuba AD. Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis 2002; 34:1391-1395.
16. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287: 650-654.
17. Anderson RM, Gupta S, May RM. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. Nature 1991; 350:356-359.
18. Stolte IG, Coutinho RA. Risk behaviour and sexually transmitted diseases are on the rise in gay men, but what is happening with HIV? Curr Opin Infect Dis 2002; 15:37-41.
19. Stephenson JM, Imrie J, Davis MM, et al. Is use of antiretroviral therapy among homosexual men associated with increased risk of transmission of HIV infection? Sex Transm Infect 2003; 79:7-10.
20. Wadman M. Expert clash over likely impact of cheap AIDS drugs in Africa. Nature 2001; 410:615-616.
21. Telenti A, Rizzardi GP. Limits of potent antiretroviral therapy. Rev Med Virol 2000; 10:385-393.
22. Blower SM, van Griensven GJP. Effect of differential mortality on risk behaviour change in cohort studies. J Acquir Immune Defic Syndr 1993; 6:1365-1367.
23. Kault DA. Modelling the effects of AIDS on gonorrhea epidemiology. Mathl Comput Modelling 1992; 16:3-14.
24. Chesson HW, Thomas SD, Sevgi AO. AIDS mortality may have contributed to the decline in syphilis rates in the United-States in the 1990s. Sex Transm Dis 2003; 30:419-425.
25. Boily M-C, Bastos FI, Hogben M, Godin G. The putative impact of HAART on individual sexual behavior. XIV International AIDS Conference; Barcelona, Spain; July 7-12, 2002 (PeWe6360).
26. Boily MC, Masse B, Desai K. The impact of HIV antiretroviral therapy (ART) on STD trends with time. ISSTDR; Berlin; 2001; Abstract #T113.
27. Van de Ven P, Rawstorne P, Nakamura T, Crawford J, Kippax S. HIV treatments optimism is associated with unprotected anal intercourse with regular and with casual partners among Australian gay and homosexually active men. Int J STD AIDS 2002; 13:181-183.
28. Elford J, Bolding G, Sherr L. High-risk sexual behaviour increases among London gay men between 1998 and 2001: what is the role of HIV optimism? AIDS 2002; 16:1537-1544.
29. Knox S, Van de Ven P, Prestage G, et al. Increasing realism among gay men in Sydney about HIV treatments: changes in attitude over time. Intl J STD AIDS 2001; 12:310-314.
30. Miller M, Meyer L, Boufassa F, et al. Sexual behavior changes and protease inhibitor therapy. SEROCO Study Group. AIDS 2000; 14:F33-F39.
31. Suarez TP, Kelly JA, Pinkerton SD, et al. Influence of a partner's HIV serostatus, use of highly active antiretroviral therapy, and viral load on perceptions of sexual risk behavior in a community sample of men who have sex with men. J Acquir Immune Defic Syndr 2001; 28:471-477.
32. Kelly JA, Raymond GH, Rompa D, Gray M. Protease inhibitor combination therapies and perceptions of gay men regarding AIDS severity and the need to maintain safer sex. AIDS 1998; 12:F91-F95.
33. Elford J, Bolding G, Maguire M, Sherr L. Combination therapies for HIV and sexual risk behavior among gay men. J Acquir Immune Defic Syndr 2000; 23:266-271.
34. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-1 infection results in suppression of the seminal shedding of HIV. AIDS 2000; 14:117-121.
35. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294.
36. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-493.
37. van de Laar MJW, Pickering J, van den Hoek JAR, et al. Declining gonorrhoea rates in The Netherlands, 1976-88: consequences for the AIDS epidemic. Genitourin Med 1990; 66:148-155.
38. Carne CA, Weller JVD, Johnson AM, et al. Prevalence of antibodies to human immunodeficiency virus, gonorrhoea rates, and changed sexual behaviour in homosexual men in London. Lancet 1987; i: 119-121.
39. Catania JA, Osmond D, Stall RD, et al. The continuing HIV epidemic among men who have sex with men. Am J Public Health 2001; 91:907-914.
40. Fay RE, Turner CF, Klassen AD, Gagon JH. Prevalence and patterns of same-gender sexual contact among men. Science 1989; 243: 338-348.
41. Archibald CP, et al. Estimating the size of hard-to-reach populations: a novel method using HIV testing data compared to other methods. AIDS 2001; 15:S41-S48.
42. Centers for Disease Control and Prevention. Guidelines for using Antiretroviral agents among HIV-infected adults and adolescents. Recommendation of the panel on clinical practices for treatment of HIV. MMWR Morb Mortal Wkly Rep 2002; 51(RR-7):56.
43. Bastos FI, Kerrigan D, Malta M, Carneiro-da-Cunha C, Strathdee SA. The provision of treatment for HIV/AIDS in Brazil: strengths, challenges, and opportunities for operations research. AIDS Science 2001; 1:1-17.
44. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001; 15:369-378.
45. Cohen C, Revicki DA, Nabulsi A, et al. A randomized trial of the effect of ritonavir in maintaining the quality of life in advanced HIV disease. AIDS 1998; 12:1495-1502.
46. Gilliam BL, Dyer JR, Fiscus SA, et al. Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen. J Acquir Immune Defic Syndr 1997; 15:54-60.
47. Leruez-Ville M, et al. Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: a 18 months longitudinal study (ANRS EP012). AIDS 2002; 16:486-488.
48. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus typel-infected men at all stages of disease and its reduction by therapy with protease and non-nucleoside reverse transcriptase inhibitors. J Virol 1997; 71:6271-6275.
49. Kashuba ADM, Dyer JR, Kramer, et al. Antiretroviral-Drug concentration in semen: implication for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43:1817-1826.
50. Quinn TC, Wawer MJ, Sewankambo N, et al. for the Rakai Project Study Group. Viral load and heterosexual transmission of immunodeficiency virus type 1. N Engl J Med 2000; 342:921-929.
51. Chakraborty H, Pranab KS, Helms RW, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empirical model. AIDS 2001; 15:621-626.
52. Detels R, Alvaro M, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998; 280:1497-1503.
53. Schwarcz AK, Hsu LC, Vittinghoff E, Katz MH. Impact of protease inhibitors and other antiretroviral treatments on acquired immune deficiency syndrome survival in San Francisco, California, 1987-1996. Am J Epidemiol 2000; 152:178-185.
54. Palella FJ, Dellaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
55. The Cascade Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355:1158-1159.
56. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001; 285:1308-1315.
57. Berrey MM, Schacker T, Collie AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduced frequency of rapid progression to AIDS. J Infect Dis 2001; 183:1466-1475.
58. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. ICONA Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499-507.
59. Howard AA, Arnsten JH, Lo Y, et al., the HER Study Group. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002; 16:2175-2182.
60. Masquelier B, Peytavin G, Leport C, et al., APROCO Study Group. Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study. J Infect Dis 2002; 186:1503-1507.
61. Brenner BG, Turner D, Wainberg MA. HIV drug resistance: can we overcome? Expert Opin Biol Ther 2002; 7:751-761.
62. Tanuri A, Caridea E, Dantas MC, et al. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 2002; 25:39-46.
63. Leigh Brown AJ, Frost SD, Mathews WC, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683-686.
64. Bochow M, Chiarotti F, Davies P, et al. Sexual behaviour of gay and bisexual men in eight European countries. AIDS Care 1994; 6:533-549.
65. Veugelers PJ, Van Zessen G, Hendricks H, et al. Estimation of the magnitude o the HIV epidemic among homosexual men: utilization of survey data in predictive models. Eur J Epidemiol 1993; 9:436-441.
66. Evans BG, McLean KA, Dawson SG, et al. Sexually transmitted diseases and HIV-1 infection among homosexual men in England and Wales. BMJ 1989; 298:215-218.
67. http.//www.hc-sc.gc.ca/pphb-dgspsp/publicat/epiu-aepi/hiv-vih/msm_e.html.
68. http.//www.walnet.org/members/dan_allman/mutualacts/chapter08.html.
69. Torian LV, Weisfuse IB, Makki HA, et al. Trends in seroprevalence in men who have sex with men: New York City department of health sexually transmitted diseases clinics, 1988-1993. AIDS 1996; 10:187-192.
70. Martin JL, Garcia MA, Beatrice ST. Sexual behaviour changes and HIV antibody in a cohort of New-York city gay men. Am J Public Health 1989; 79:501-503.
71. Weinkelstein W Jr, Samuel M, Padian NS, et al. The San Francisco Men's Health Study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-1986. Am J Public Health 1987; 77:685-689.
72. Golombok S, Sketchley J, Rust J. Condom use among homosexual men. AIDS Care 1989; 1:27-33.
73. Judson FN, Miller KG, Schaffnit TR. Screening for gonorrhea and syphilis in the gay baths-Denver, Colorado. Am J Public Health 1977; 67:740-742.
74. McKusick L, Wiley JA, Coates TJ, Stall G. Reported changes in the sexual behaviour in men at risk from AIDS, San Francisco 1982-1984: the AIDS Behaviour Research Project. Public Health Rep 1985; 100:622-629.
75. Jacquez JA, Koopman JS, Simon CP, et al. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7:1169-1184.
76. Lau RK, Jenkins P, Caun K, et al. Trends in sexual behaviour in a cohort of homosexual men: a 7 year prospective study. Int J STD AIDS 1992; 3:267-272.
77. Piaseczna MA, Craib KJ, Li K, et al. Longitudinal patterns of sexual behavior and condom use in a cohort of HIV-negative gay and bisexual men in Vancouver, British Columbia, Canada, 1995-2000. J Acquir Immune Defic Syndr 2001; 28:187-193.
78. van Griensven GJ, de Vroome EM, Goudsmith J, Coutinho RA. Changes in sexual behaviour and the fall in incidence of HIV infection among homosexual men. BMJ 1989; 298:218-221.
79. Ferry B, Carael M, Buve A, et al. Comparison of key parameters of sexual behaviour in four African urban populations with different levels of HIV infection. AIDS 2001; 15(suppl 4):S41-S50.
80. Anderson RM, May RM, Boily MC, et al. The spread of HIV-1 in Africa: sexual contact patterns and the predicted demographic impact of AIDS. Nature 1991; 15:581.
81. Fonseca MG, Bastos FI, Derrico M, Andrade CL, Travassos C, Szwarcwald CL. AIDS and level of education in Brazil: temporal evolution from 1986 to 1996. Cad Saude Publica 2000; 16(suppl 1):77-87.
82. Stall P, Pollack L, Mills TC, et al. Use of antiretroviral therapies among HIV infected men who have sex with men: a household based sample of 4 major Am cities. Am J Public Health 2001; 91:767-773.
83. Johnson AM, Gill ON. Evidence for recent changes in sexual behaviour in homosexual men in England and Wales. Philos Trans R Soc Lond B Biol Sci 1989; 325:153-161.
84. Wardropper AG, Pattman RS. Gonorrhoea as an indicator of altered sexual behaviour and as a surrogate marker of HIV concern: a 13-year analysis in Newcastle. Int J STD AIDS 1995; 6:348-350.
85. Anderson JE, Stall R. Increased reporting of male-to-male sexual activity in a national survey. Sex Transm Dis 2002; 29:643-646.
86. Boily MC, Lowndes CM, Gregson S. Population-level risk factors for HIV transmission and 'the 4 Cities Study': temporal dynamics and the significance of sexual mixing patterns. AIDS. 2002; 16:2101-2102.
87. Centers for Disease Control and Prevention. Resurgent bacterial sexually transmitted diseases among men who have sex with men-King County, Washington. MMWR Morb Mortal Wkly Rep 1997; 48:773-777.
88. Huebner DM, Gerend MA. The relation between beliefs about drug treatments for HIV and sexual risk behavior in gay and bisexual men. Ann Behav Med 2001; 23:304-312.
89. Dukers NHTM, Spaargaren J, Geskus RB, et al. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using of a novel approach for detecting recent infections. AIDS 2002; 16:F19-F24.
90. Kellog T, McFarland W, Katz M. Recent increases in HIV seroconversion among repeat anonymous testers in San Francisco. AIDS 1999; 13:2303-2316.
91. del Romero J, Castilla J, Garcia S, et al. Time trend in incidence of HIV seroconversion among homosexual men repeatedly tested in Madrid, 1988-2000. AIDS. 2001; 15:1319-1321.
92. Hogg RS, Weber AE, Chan K, et al. Increasing incidence of HIV infections among young gay and bisexual men in Vancouver. AIDS 2001; 15:1321.
93. Wasserheit J. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
94. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994; 344:246-248.
95. Yorke JA, Hethcote HM, Nold A. Dynamics and control of the transmission of gonorrhea. Sex Transm Dis 1978; 5:51-57.
96. Nielsen R, Sondergaard J, Ullman S. Asymptomatic male and female gonorrhoea. Acta Derm Venereol 1975; 55:499.
97. Holmes KK, et al., eds. Sexually Transmitted Diseases, 3rd ed. New York: McGraw-Hill; 1999.
98. Garnett GP, Mertz KJ, Finelli L, et al. The transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients from Newark, New Jersey. Philos Trans R Soc Lond B Biol Sci 1999; 354:787-797.
99. Felton WF. Contrasting views on the infectivity of gonorrhoea. Br J Vener Dis 1973; 49:151-154.
100. Holmes KK, Johnson DW, Trostle HJ. An estimate of the risk of men acquiring gonorrhea by sexual contact with infected females. Am J Epidemiol 1970; 91:170-174.
101. Vittinghoff E, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306-311.
102. DeGruttola V, Seage GR, Mayer KH, Horsburgh CR. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989; 42:849-856.
103. Jacquez JA, et al. J Acquir Immune Defic Syndr 1994; 7:1169-1184.
104. Lemp GP, et al. Projections of AIDS morbidity and mortality in San Francisco, JAMA 1990; 263:1538-1542.
105. Egger M, May M, Chêne G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
106. Collaborative Group on AIDS Incubation, HIV Survival. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on Seroconversion to AIDS and Death in Europe. Lancet 2000; 355:1131-1137.